Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

NCT01776788 on ClinicalTrials.gov · last registry update 2015-03-10

An unusually large phase 4: 156 participants, more than double the 75 typical for the stage. The sponsor logged completion for February 2015. Primary outcome, as filed: the glycemic remission rate in different groups. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: The First Affiliated Hospital of Xiamen University
Sponsor type: Other
Enrollment: 156
Started: 2012-08
Primary completion: 2015-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

the glycemic remission rate in different groups

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.